BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7915095)

  • 21. Expression of the ets-1 proto-oncogene in melanocytic lesions.
    Keehn CA; Smoller BR; Morgan MB
    Mod Pathol; 2003 Aug; 16(8):772-7. PubMed ID: 12920221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
    Wilbur DC; Barrows GH
    Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The correlation of c-erbB-2 oncoprotein and established prognostic factors in human breast cancer.
    Sütterlin MW; Haller A; Gassel AM; Peters K; Caffier H; Dietl J
    Anticancer Res; 2000; 20(6D):5083-8. PubMed ID: 11326673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunohistochemical tumor markers in infiltrating ductal breast carcinoma].
    Gallegos M; González S; León A; Claure R; Goñi I; Andrade L; Duarte I
    Rev Med Chil; 1998 Oct; 126(10):1216-23. PubMed ID: 10030093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunohistochemical study on the expression of c-erbB2 oncoprotein in breast tumors].
    Zhang Z; Xu G; Liu S
    Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):287-9. PubMed ID: 11038761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies of c-jun oncogene expression in human breast using a new monoclonal antibody, NCL-DK4.
    Tiniakos DG; Scott LE; Corbett IP; Piggott NH; Horne CH
    J Pathol; 1994 Jan; 172(1):19-26. PubMed ID: 7931823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of c-erbB-2 oncogene and p53 tumor suppressor gene in benign and malignant breast tissue: correlation with proliferative activity and prognostic index.
    Alexiev BA; Bassarova AV; Popovska SL; Popov AA; Christov CZ
    Gen Diagn Pathol; 1997 Jun; 142(5-6):271-9. PubMed ID: 9228249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
    Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
    Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction.
    Naidu R; Wahab NA; Yadav M; Kutty MK
    Int J Mol Med; 2002 Feb; 9(2):189-96. PubMed ID: 11786932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas.
    Yi ES; Harclerode D; Gondo M; Stephenson M; Brown RW; Younes M; Cagle PT
    Mod Pathol; 1997 Feb; 10(2):142-8. PubMed ID: 9127320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. c-KIT expression in columnar cell lesions of the breast accompanied by benign and malignant breast diseases.
    Polat A
    Pathol Res Pract; 2007; 203(11):765-9. PubMed ID: 17931792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. c-erbB-2 expression in FNAB smears and matched surgical specimens of breast cancer.
    Troncone G; Panico L; Vetrani A; de Divitiis B; Zeppa P; Fulciniti F; Pettinato G; Palombini L
    Diagn Cytopathol; 1996 Mar; 14(2):135-9. PubMed ID: 8964169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical detection of c-erbB-2 oncoprotein in patients with breast cancer.
    Chariyalertsak S; Chariyalertsak S; Cheirsilpa A; Sugano K; Ohkura H
    J Med Assoc Thai; 1996 Nov; 79(11):715-21. PubMed ID: 8997010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between histological grade and c-erbB2 oncoprotein overexpression in infiltrating ductal carcinoma of breast.
    Looi LM; Cheah PL; Yap SF
    Malays J Pathol; 1997 Jun; 19(1):35-9. PubMed ID: 10879240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients.
    Pupa SM; Ménard S; Andreola S; Colnaghi MI
    Cancer Res; 1993 Dec; 53(24):5864-6. PubMed ID: 7903196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distribution of prognostically unfavourable product of c-erbB-2 oncogene and EGF-R in carcinomas of the breast and uterine cervix.
    Ray A; Naik SL; Sharma BK
    Indian J Physiol Pharmacol; 2002 Oct; 46(4):423-33. PubMed ID: 12683217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BigH3 protein expression as a marker for breast cancer.
    Calaf GM; Echiburú-Chau C; Zhao YL; Hei TK
    Int J Mol Med; 2008 May; 21(5):561-8. PubMed ID: 18425347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
    Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
    Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
    Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HYOU1/Orp150 expression in breast cancer.
    Stojadinovic A; Hooke JA; Shriver CD; Nissan A; Kovatich AJ; Kao TC; Ponniah S; Peoples GE; Moroni M
    Med Sci Monit; 2007 Nov; 13(11):BR231-239. PubMed ID: 17968289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.